Mobius Care

Mobius Care is a precision medicine company dedicated to transforming inflammatory bowel disease treatment. Founded by world-renowned IBD researcher Dr. Thaddeus Stappenbeck at Cleveland Clinic, we are pioneering innovative diagnostics and therapeutics that address the critical unmet needs in IBD. By leveraging advanced AI, multimodal patient data, and breakthrough scientific discoveries, we aim to shift standard of care from a one-size-fits-all approach to personalized, targeted care that improves patient outcomes and quality of life. Mobius’s AI pathology tool, based on its proprietary patented biomarker, maps gut topography rapidly to differentiate responders from non-responders to IBD medication. Mobius offers patient stratification solutions to clinical-stage pharma companies to increase the efficacy of IBD drugs under development. Our mission is to usher in a new era of inflammatory bowel disease (IBD) care through precision medicine. Grounded in clinical and scientific evidence, we are developing novel diagnostics and therapeutics precisely tailored to each patient’s unique biology. Driven by innovation and our unwavering commitment to improving patient lives, we aspire to deliver solutions that outperform current standard of care.